http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104208063-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4706 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P33-02 |
| filingDate | 2014-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-104208063-B |
| titleOfInvention | Insulin-like growth factor acceptor inhibitor PQ401 is as the application of preparation treatment echinococcosis granulosa medicine |
| abstract | The present invention relates to insulin-like growth factor acceptor inhibitor PQ401 technical field, be a kind of insulin-like growth factor acceptor inhibitor PQ401 application as preparation treatment echinococcosis granulosa medicine.Insulin-like growth factor acceptor inhibitor PQ401 of the present invention is a kind of novel anti-treating echinococcosis；Internal and external both sides pharmacodynamic experiment data, all show that PQ401 is a kind of efficient anti-treating echinococcosis molecule, it is possible to destroy Echinococcus Granulosus Cysts vesicle organizational structure, cause vesicle Echinococcus Granulosus Cysts follicle cell the most downright bad；Internal pharmacodynamic experiment data show that the drug effect of the Albendazole In Treatment echinococcosis granulosa that this medicine is conventional with clinic is suitable；In view of clinical patients with hydatidosis long-term taking albendazole can cause drug resistance, therefore this medicine can carry out treating echinococcosis as the succedaneum of albendazole. |
| priorityDate | 2014-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 62.